Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire    SHP   JE00B2QKY057

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Shire PLC : Shire Buys 50,953 Own Shares to Hold in Treasury

share with twitter share with LinkedIn share with facebook
share via e-mail
02/22/2013 | 09:57am CEST

LONDON--Biopharmaceutical company Shire PLC (SHP.LN), said Friday it purchased 50,953 of its ordinary shares of 5 pence each on February 21, through both direct purchases of Ordinary Shares and through the purchase of Ordinary Shares underlying ADRs.


-The purchased shares will be held as treasury shares

-The highest and lowest price paid for the directly acquired Ordinary Shares was 2083.00 pence per share and 2047.00 pence per share respectively and for those Ordinary Shares acquired through the purchase of ADRs was 3148.50 cents per share and 3139.33 cents per share respectively.

-Shire shares at 0840 GMT traded up 5.0 pence, or 0.2%, at GBP20.77, valuing the company at GBP11.55 billion.

-Write to Razak Musah Baba at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SHIRE
06:43p FTSE rises to record close, blue-chips shrug off Reckitt blip
10/17 SHIRE : New Formulation of ONCASPAR Receives Positive CHMP Opinion in Europe for..
10/14 SHIRE : Activist fund seeks break-up of £35bn pharma group Shire
10/13 SHIRE PLC : New Formulation of ONCASPAR® (pegaspargase) Receives Positive CHMP O..
10/13 SHIRE : New Formulation of ONCASPAR® (pegaspargase) Receives Positive CHMP Opini..
10/12 SHIRE PLC : Financial Statements and Exhibits (form 8-K)
10/12 SHIRE : to announce third quarter 2017 results
10/12DJSHIRE PLC SHIRE PLC : Notice Of Results
10/12 SHIRE PLC : Notice of Results
10/05 SHIRE PLC : Financial Statements and Exhibits (form 8-K)
More news
News from SeekingAlpha
12:03p Shire feels Amgen's Restasis patent pain, shares down 3%
10/16 YOUR DAILY PHARMA SCOOP : ACRX Second Chance, AERI Rhopressa Success, Aratana EN..
10/13 European advisory group backs Shire's lyophilized Oncaspar for ALL
10/12 SHIRE Q3/2017 : Earnings Preview
10/12 YOUR DAILY PHARMA SCOOP : AcelRx DSUVIA PDUFA, Ardelyx Phase 3 Success, Rhopress..
Financials ($)
Sales 2017 14 973 M
EBIT 2017 5 586 M
Net income 2017 2 577 M
Debt 2017 19 246 M
Yield 2017 0,71%
P/E ratio 2017 17,21
P/E ratio 2018 12,37
EV / Sales 2017 4,37x
EV / Sales 2018 3,95x
Capitalization 46 206 M
Duration : Period :
Shire Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Technical analysis trends SHIRE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 69,0 $
Spread / Average Target 36%
EPS Revisions
Flemming Ornskov Chief Executive Officer & Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
Jeffrey Poulton Chief Financial Officer & Executive Director
Philip J. Vickers Global Head-Research & Development
Matt Walker Head-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE-17.85%46 206
JOHNSON & JOHNSON18.42%377 880
NOVARTIS13.23%225 650
ROCHE HOLDING LTD.5.20%217 022
PFIZER11.88%215 576